219 related articles for article (PubMed ID: 21696764)
1. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.
Al Mushawah F; Rastelli A; Pluard T; Margenthaler JA
J Surg Res; 2012 Mar; 173(1):10-5. PubMed ID: 21696764
[TBL] [Abstract][Full Text] [Related]
2. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
3. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
5. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
6. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
8. Influence of local treatment on the recurrence rate of ductal carcinoma in situ.
Warneke J; Grossklaus D; Davis J; Stea B; Bebb G; Taylor C; Hastings R; Villar H
J Am Coll Surg; 1995 Jun; 180(6):683-8. PubMed ID: 7773481
[TBL] [Abstract][Full Text] [Related]
9. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
10. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
11. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.
Boyages J; Delaney G; Taylor R
Cancer; 1999 Feb; 85(3):616-28. PubMed ID: 10091735
[TBL] [Abstract][Full Text] [Related]
12. Analyzing the risk of recurrence after mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index.
Kelley L; Silverstein M; Guerra L
Ann Surg Oncol; 2011 Feb; 18(2):459-62. PubMed ID: 20859695
[TBL] [Abstract][Full Text] [Related]
13. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
14. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast.
Lee LA; Silverstein MJ; Chung CT; Macdonald H; Sanghavi P; Epstein M; Holmes DR; Silberman H; Ye W; Lagios MD
Am J Surg; 2006 Oct; 192(4):416-9. PubMed ID: 16978940
[TBL] [Abstract][Full Text] [Related]
17. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
Dzierzanowski M; Melville KA; Barnes PJ; MacIntosh RF; Caines JS; Porter GA
J Surg Oncol; 2005 May; 90(2):71-6. PubMed ID: 15844190
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ductal carcinoma in situ of the breast: review of recent advances and future prospects.
Mokbel K
Int J Fertil Womens Med; 2003; 48(5):217-25. PubMed ID: 14626378
[TBL] [Abstract][Full Text] [Related]
19. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy.
Noh JM; Lee J; Choi DH; Cho EY; Huh SJ; Park W; Nam SJ; Lee JE; Kil WH
Breast; 2013 Oct; 22(5):894-7. PubMed ID: 23643805
[TBL] [Abstract][Full Text] [Related]
20. Results of 23,810 cases of ductal carcinoma-in-situ.
Sumner WE; Koniaris LG; Snell SE; Spector S; Powell J; Avisar E; Moffat F; Livingstone AS; Franceschi D
Ann Surg Oncol; 2007 May; 14(5):1638-43. PubMed ID: 17245612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
